- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Amicus Therapeutics Inc (FOLD)
Amicus Therapeutics Inc stock price live, this page displays NASDAQ FOLD stock exchange data. View the FOLD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Amicus Therapeutics Inc real time stock price chart below.
What Is the Amicus Therapeutics Inc Stock Price Today?
The Amicus Therapeutics Inc stock price today is 14.490.
What Is the Stock Symbol for Amicus Therapeutics Inc?
The stock symbol for Amicus Therapeutics Inc is "FOLD."
What Stock Exchange Does Amicus Therapeutics Inc Trade On?
Amicus Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Amicus Therapeutics Inc a Good Stock to Buy?
Determining whether Amicus Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FOLD quote. (ISIN: US03152W1099) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
What Is the Amicus Therapeutics Inc Stock Price Today?
The Amicus Therapeutics Inc stock price today is 14.490.
What Is the Stock Symbol for Amicus Therapeutics Inc?
The stock symbol for Amicus Therapeutics Inc is "FOLD."
What Stock Exchange Does Amicus Therapeutics Inc Trade On?
Amicus Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Amicus Therapeutics Inc a Good Stock to Buy?
Determining whether Amicus Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FOLD quote. (ISIN: US03152W1099) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
14.490
+0.030(+0.21%)
Real-time Data·
Fair Value
An estimate of a Amicus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.490
14.500
52 wk Range
5.510
14.500
Showing Amicus historical data. For real-time data please try another search
Fair Value
An estimate of a Amicus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.49014.500
52 wk Range
5.51014.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FOLD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Amicus's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
14.500
Upside
+0.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.
Amicus Therapeutics Inc Earnings Call Summary for Q3/2025
- Amicus Therapeutics exceeded Q3 2025 expectations with EPS of $0.06 (100% above forecast) and revenue of $169.1 million (19% YoY growth), resulting in a 1.02% pre-market stock increase.
- The company reported its first quarter of GAAP net income at $17.3 million and non-GAAP net income of $54.2 million, with cash reserves increasing by $32.8 million to $263.8 million.
- Strong performance was driven by Galafold (12% growth, 69% market share) and Pombiliti/Opfolda (42% revenue surge) with successful international market expansion.
- Management projects 15-22% total revenue growth for 2025, with Galafold growing 10-15% and Pombiliti/Opfolda increasing 50-65%, targeting combined sales of $1 billion by 2028.
- The company is pursuing label expansions for its products while addressing challenges including market competition, regulatory hurdles, and potential supply chain disruptions.
Last Updated: 04/11/2025, 15:54
Read Full TranscriptCompare FOLD to Peers and Sector
Metrics to compare | FOLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFOLDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −167.8x | 7.3x | −0.5x | |
PEG Ratio | −3.21 | 0.10 | 0.00 | |
Price/Book | 16.6x | 2.9x | 2.6x | |
Price / LTM Sales | 7.2x | 5.0x | 3.2x | |
Upside (Analyst Target) | 0.1% | 221.6% | 47.4% | |
Fair Value Upside | Unlock | 8.4% | 6.9% | Unlock |
Analyst Ratings
0 Buy
6 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 14.500
(+0.07% Upside)
Earnings
Latest Release
Feb 20, 2026
EPS / Forecast
0.01 / 0.07
Revenue / Forecast
185.21M / 179.77M
People Also Watch
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.